a Lin He's Academician Workstation of New Medicine and Clinical Translation at The Third Affiliated Hospital , Guangzhou Medical University , Guangzhou , P.R. China.
b Department of Medicine, Division of Regenerative Medicine , University of California San Diego , San Diego , CA , USA.
Expert Opin Biol Ther. 2019 Feb;19(2):141-148. doi: 10.1080/14712598.2019.1559293. Epub 2018 Dec 24.
Natural killer (NK) cell therapy has been proven to be safe and clinically effective for the treatment of multiple cancers, in particular blood cancers. Most of the clinical trials use primary NK cells from peripheral blood or umbilical cord blood, or NK-92 cells. Each cell source is confined by limitations, such as donor dependence, low persistence , and its difficulty to genetically modify. Thus, there is an urgent need to explore novel NK cell sources for clinical use.
This article highlights the recent progress in utilizing stem cell-derived NK cells as anticancer therapies and strategies to improve their antitumor activities.
Stem cell-derived NK cells are homogenous, easy to genetically modify on a clonal level, and can be expanded to clinical scale. They may therefore arise as an ideal population for developing off-the-shelf, standardized adoptive NK cell therapeutic products.
自然杀伤 (NK) 细胞疗法已被证明可安全有效地治疗多种癌症，尤其是血液癌症。大多数临床试验使用来自外周血或脐带血的原代 NK 细胞，或 NK-92 细胞。每种细胞来源都受到限制，例如供体依赖性、低持久性以及其遗传修饰的难度。因此，迫切需要探索用于临床的新型 NK 细胞来源。
本文重点介绍了利用干细胞衍生的 NK 细胞作为抗癌疗法的最新进展，以及提高其抗肿瘤活性的策略。
干细胞衍生的 NK 细胞具有均一性，易于在克隆水平上进行遗传修饰，并且可以扩增到临床规模。因此，它们可能成为开发现成的、标准化的过继性 NK 细胞治疗产品的理想群体。
